EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to tame rare inflammatory disease
Disease control OngoingThis phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patient…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug may tame rare vasculitis and cut steroid dependence
Disease control OngoingThis study tests whether a drug called mepolizumab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab or usual care, and…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC